Krystal Biotech, Inc. KRYS Accrued Expenses And Other Current Liabilities
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept krys:AccruedExpensesAndOtherCurrentLiabilities.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s accrued expenses and other current liabilities.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s accrued expenses and other current liabilities?
- Krystal Biotech, Inc. (KRYS) reported accrued expenses and other current liabilities of $31.2M in Q1 2026.
- How has Krystal Biotech, Inc.'s accrued expenses and other current liabilities changed year-over-year?
- Krystal Biotech, Inc.'s accrued expenses and other current liabilities increased by 11.2% year-over-year, from $28.05M to $31.2M.
- What is the long-term trend for Krystal Biotech, Inc.'s accrued expenses and other current liabilities?
- Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s accrued expenses and other current liabilities has grown at a 50.7% compound annual growth rate (CAGR), from $5.11M to $39.75M.